Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this trial is: • to compare the overall survival (OS) of patients in the rigosertib group vs the Physician`s Choice group, in all patients and in a subgroup of patients with IPSS-R (Revised International Prognostic Scoring System) very high risk.
Critère d'inclusion
- myelodysplastic syndrome